Press release
PI3K Inhibitor Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight
Download DelveInsight's comprehensive PI3K Inhibitor Pipeline Report @ PI3K Inhibitor Pipeline Outlook Report [https://www.delveinsight.com/sample-request/pi3k-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the PI3K Inhibitor Pipeline Report
* On March 20, 2026, Eli Lilly and Company initiated a phase 3 study is to assess the efficacy and safety of the addition of Tersolisib (LY4064809/STX-478) to other anti-cancer drugs as first treatment for advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Participants can remain in the study as long as the drug is helping the cancer without unbearable side effects.
* On March 18, 2026, Vividion Therapeutics Inc. announced a phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of VVD-159642, a rat sarcoma viral oncogene-phosphatidylinositol 3-kinase alpha (RAS-PI3K) inhibitor, as a single agent and in combination with either sotorasib or trametinib in participants with advanced solid tumors.
* DelveInsight's PI3K Inhibitor Pipeline analysis depicts a robust space with 20+ active players working to develop 25+ pipeline treatment therapies.
* The leading PI3K Inhibitor Companies such as Celcuity, ThromBio, Suzhou Teligene, BeBetter Med Inc, Kazia Therapeutics, Risen Pharma, Advenchen Laboratories, Curis, Leapfrog Bio, Cogent Biosciences and others.
* Promising PI3K Inhibitor Pipeline Therapies such as Evexomostat, Copanlisib, fulvestrant, BKM120, BYl719 , and others.
Access DelveInsight's in-depth PI3K Inhibitor Pipeline Analysis for a closer look at promising breakthroughs @ PI3K Inhibitor Clinical Trials and Studies [https://www.delveinsight.com/sample-request/pi3k-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
PI3K Inhibitor Overview
Phosphoinositide 3-kinases (PI3Ks) are a family of enzymes involved in key cellular functions such as growth, proliferation, metabolism, and survival. The PI3K/AKT/mTOR signaling pathway is frequently activated in many types of cancer, often due to genetic mutations, particularly in the PIK3CA gene. This has made PI3Ks attractive targets for cancer therapy, and several inhibitors have been developed to block this pathway and suppress tumor growth.
PI3K Inhibitor Emerging Drugs Profile
* Gedatolisib: Celcuity
Gedatolisib is a dual inhibitor of PI3K and mTOR, targeting all class I isoforms of PI3K and mTORC1 and mTORC2. This unique mechanism of action distinguishes it from other inhibitors that target PI3K or mTOR alone. Gedatolisib aims to address drug resistance and potential resistance mechanisms that can occur with isoform-specific inhibitors. The drug has shown promising results in clinical trials, demonstrating manageable toxicity and potential efficacy in combination therapies for hormone receptor-positive, HER2-negative metastatic breast cancer patients who progressed after CDK4/6 inhibitor treatment. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Breast cancer.
* TBO-309: ThromBio
TBO-309 is a novel antiplatelet compound with truly remarkable properties. TBO-309 is a potent, selective and ATP competitive PI3K [beta] inhibitor which reduces platelet activation adhesion/aggregation particularly under conditions of disturbed blood flow and promotes platelet disaggregation. By targeting PI3K [beta], TBO-309 specifically inhibits thrombosis whilst minimizing the impact on normal hemostasis. A key point of differentiation between TBO-309 and currently approved antiplatelets is its wide therapeutic window. When combined with existing anti-clotting therapies, it does not cause a major increase in bleeding. This has been confirmed in several proof-of-concept studies in both animal models and two Phase I human clinical trials. In a broad range of preclinical animal models, and in two Phase I human clinical trials studies have demonstrated that TBO-309 (AZD6482) can inhibit arterial thrombus formation in a dose-dependent manner, without causing a major increase in bleeding and TBO-309 can be safely and effectively combined with other antithrombotic agents without causing a major increase in bleeding. Currently, the drug is in Phase II Stage of its clinical development for the treatment of Ischemic Stroke and Tandem Occlusion.
* TL117: Suzhou Teligene
TL117 is an orally bioavailable Phosphatidylinositol 3-Kinase (PI3K) inhibitor, with potential antineoplastic activity. Upon oral administration, PI3K inhibitor TL117 specifically inhibits the activity of PI3K, and prevents the activation of the PI3K/Akt (protein kinase B)-mediated signaling pathway. This may result in the inhibition of both tumor cell growth and survival in PI3K-overexpressing tumor cells. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents. Currently, the drug is in Phase I/II Stage of its clinical development for the treatment of Head and Neck Squamous Cell Carcinoma.
The PI3K Inhibitor Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of PI3K Inhibitor with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for PI3K Inhibitor Treatment.
* PI3K Inhibitor Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* PI3K Inhibitor Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the PI3K Inhibitor market
Explore groundbreaking therapies and clinical trials in the PI3K Inhibitor Pipeline @ New PI3K Inhibitor Drugs [https://www.delveinsight.com/sample-request/pi3k-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
PI3K Inhibitor Companies
Celcuity, ThromBio, Suzhou Teligene, BeBetter Med Inc, Kazia Therapeutics, Risen Pharma, Advenchen Laboratories, Curis, Leapfrog Bio, Cogent Biosciences and others
PI3K Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
PI3K Inhibitor Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Download DelveInsight's latest report to gain strategic insights into upcoming therapies @ PI3K Inhibitor Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/pi3k-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the PI3K Inhibitor Pipeline Report
* Coverage- Global
* PI3K Inhibitor Companies- Celcuity, ThromBio, Suzhou Teligene, BeBetter Med Inc, Kazia Therapeutics, Risen Pharma, Advenchen Laboratories, Curis, Leapfrog Bio, Cogent Biosciences and others.
* PI3K Inhibitor Pipeline Therapies- Evexomostat, Copanlisib, fulvestrant, BKM120, BYl719 , and others.
* PI3K Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* PI3K Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find out in DelveInsight's exclusive PI3K Inhibitor Pipeline Report-access it now! @ PI3K Inhibitor Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/pi3k-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* PI3K Inhibitor: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* PI3K Inhibitor - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Gedatolisib: Celcuity
* Mid Stage Products (Phase II)
* TBO-309: ThromBio
* Early Stage Products (Phase I/II)
* TL117: Suzhou Teligene
* Preclinical Stage Products
* Drug Name: Company Name
* Inactive Products
* PI3K Inhibitor - Collaborations Assessment- Licensing / Partnering / Funding
* PI3K Inhibitor - Unmet Needs
* PI3K Inhibitor - Market Drivers and Barriers
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pi3k-inhibitor-treatment-pipeline-shows-strong-momentum-as-20-pharma-companies-in-the-race-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/pi3k-inhibitor-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release PI3K Inhibitor Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight here
News-ID: 4442548 • Views: …
More Releases from ABNewswire
Gartner auditor tests RB2B, Leadpipe, Warmly, Clearbit, 6sense, Leadfeeder - acc …
Six-week accuracy study by Gartner senior auditor reveals significant data quality gaps between Leadpipe, RB2B, Warmly, Clearbit, 6sense, Leadfeeder, Demandbase, and ZoomInfo.
WILMINGTON, DE - March 26, 2026 - An independent accuracy study of eight website visitor identification platforms [https://www.leadpipe.com/blog/website-visitor-deanonymization-guide/] has revealed significant data quality gaps between vendors. Kerrie Watson, Senior Auditor at Gartner, conducted controlled tests across three live B2B websites with approximately 25,000 combined monthly visitors, sending known contacts…
The Prime Cleaner Ranked #1 for House Cleaning in Pinecrest
Pinecrest homeowners rank The Prime Cleaner as the top house cleaning service in the area, citing reliability, thoroughness, and consistent five-star results in the prestigious South Miami-Dade neighborhood.
PINECREST, FL - The Prime Cleaner has been ranked the number one house cleaning service in Pinecrest by local homeowners, according to reviews on Google, Yelp, and Facebook. The family-owned Miami cleaning company has established a strong presence in the prestigious South Miami-Dade…
ALK Inhibitors Clinical Trial Pipeline Expands as 15+ Companies Driving Innovati …
DelveInsight's "ALK Inhibitors Pipeline Insight 2026" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the ALK Inhibitors pipeline landscape. It covers the ALK Inhibitors Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the ALK Inhibitors Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Curious about the latest updates…
SYK Inhibitors Clinical Trial Pipeline Shows Potential with Active Contributions …
DelveInsight's, "Spleen Tyrosine Kinase (SYK) Inhibitors Pipeline Insight, 2026" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen Tyrosine Kinase (SYK) Inhibitors pipeline landscape. It covers the SYK Inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead in…
More Releases for PI3K
PI3K Inhibitors Market Outlook: Roche, Novartis, and Emerging Biotechs Drive Com …
DelveInsight's comprehensive analysis reveals robust growth potential in the PI3K inhibitors market across 7MM through 2034. Key players include Roche/Genentech (ITOVEBI), Novartis (PIQRAY), Gilead Sciences (ZYDELIG), Kazia Therapeutics (Paxalisib), Celcuity (Gedatolisib), and others, with expanding applications from hematological to solid tumor indications driving market momentum.
PI3K Inhibitor Key Takeaways
*
PI3K Inhibitor market size projection: As per DelveInsight's analysis, the total market size of PI3K inhibitors in the 7MM is expected to…
PI3K Inhibitors Market Projected to Witness Massive Growth - Novartis, Gilead Sc …
PI3K Inhibitors Market Snapshot
The PI3K Inhibitors Market is projected to reach USD 2.5 billion by 2032, growing at a CAGR of 8.2% from 2025 to 2032.
Coherent Market Insights proudly presents its latest PI3K Inhibitors Market Research Report, delivering a detailed examination of the U.S. PI3K Inhibitors Market outlook from 2025 to 2032. This comprehensive analysis provides strategic forecasts at both national and regional levels, addressing evolving supply networks, payer-provider collaboration,…
Global Jak And Pi3k Signaling Pathway Market Size by Application, Type, and Geog …
According to Market Research Intellect, the global Jak And Pi3k Signaling Pathway market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The JAK and PI3K signaling pathway market is experiencing significant growth due to the increasing…
PI3K inhibitors Pipeline Insights, Clinical Trials, Emerging Therapies and Compa …
DelveInsight's, "PI3K inhibitors Pipeline Insight 2024" report provides comprehensive insights about 100+ companies and 100+ pipeline drugs based on PI3K inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the PI3K…
Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Segmentation Analysis and Glo …
Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market: Overview
Metabolism of the human body relies on a variety of factors, and proper metabolism is essential to prevent several diseases. The development of tumours inside the body is largely due to improper cycles of metabolism. Medical researchers have demonstrated commendable accountability in dealing with chronic disorders and diseases. The cellular functions that run inside the body need be controlled and manoeuvred through proper drug…
Phosphoinositide 3-Kinase (PI3K) Inhibitors Market Exclusive insight on Transfor …
Global Phosphoinositide 3-Kinase (PI3K) Inhibitors Market: Overview
Metabolism of the human body relies on a variety of factors, and proper metabolism is essential to prevent several diseases. The development of tumours inside the body is largely due to improper cycles of metabolism. Medical researchers have demonstrated commendable accountability in dealing with chronic disorders and diseases. The cellular functions that run inside the body need be controlled and manoeuvred through proper drug…
